Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

Lavanya Palavalli Parsons, MD
Published: Monday, Mar 26, 2018


Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

PARP belongs to a large family, but the PARP inhibitors that are currently approved only target a select few PARPs, Parsons notes. Her research focused on exploring the other PARPs and if they had a relationship to ovarian cancer.

Parsons found that PARP 7 was amplified in many patients with ovarian cancer, which caused them to have an overall survival benefit.  

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

PARP belongs to a large family, but the PARP inhibitors that are currently approved only target a select few PARPs, Parsons notes. Her research focused on exploring the other PARPs and if they had a relationship to ovarian cancer.

Parsons found that PARP 7 was amplified in many patients with ovarian cancer, which caused them to have an overall survival benefit.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x